SOURCE: Barrier Therapeutics, Inc.

June 07, 2005 10:00 ET

Barrier Therapeutics to Present at the Morgan Stanley Small Cap Executive Conference

PRINCETON, NJ -- (MARKET WIRE) -- June 7, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Dr. Geert Cauwenbergh, Chairman and Chief Executive Officer of Barrier Therapeutics, is scheduled to provide an update to the investment community on Barrier's marketed product and clinical-stage product pipeline at the Morgan Stanley Small Cap Executive Conference. The conference is being held from June 13-15, 2005, at The Ritz-Carlton New York Hotel in New York. Dr. Cauwenbergh is scheduled to present on Tuesday, June 14th at 2:00 pm, Eastern Time.

Dr. Cauwenbergh's presentation will also be available live via a webcast that can be accessed through the Company's website:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots" or "liver spots," and for the broader indication including related hyperpigmented lesions in Canada. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is in registration, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, fungal infections, including vaginal candidiasis and onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site:

Contact Information

  • Contact:

    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Emily Poe